Jianxin Biology: Completed the B round of financing to accelerate the phase I clinical study of the pioneering anti-tumor dual antibody products Bis5 and Bis2

Recently, Shanghai Jianxin Biomedicine Technology Co., LTD. (Jianxin Bio for short) announced the completion of the B round of financing, which was led by Hongfeng Investment, followed by Oriental Huisheng, Zhongchuang Yongjian and old shareholder Qiao Jing Capital.

This round of financing will accelerate the phase I clinical studies of Bis2 and Bis5, the two pioneering double antibody products independently developed by the company, strengthen the technical barriers of pioneering products in the segmented field of tumor therapy in the post-PD-1 era, and promote the preclinical studies of pioneering triple antibody products.

Jianxin Biologic focuses on pioneering new drug (FIC) innovation with differentiated dual and multispecific antibodies, focusing on the clinical needs of patients with ineffective PD-1 treatment and drug-resistant subdivided tumors. It has a perfect platform for the discovery of monoclonal antibody, double and multi-specific antibody, including antibody sequence discovery platform, computer modeling humanization technology platform, sequence specific IgG-like double and multi-specific antibody (SBody) platform and efficient engineering cell line platform. The core products Bis5 and Bis2 have both obtained clinical approval from China and the United States, and are currently undergoing phase I clinical studies. A number of the first three antibodies are in the pre-clinical development stage, and 2 independently developed products are authorized to be jointly developed by listed companies. More than 30 domestic and international invention patents have been applied and authorized. Jianxin Biology is a high-tech enterprise in Shanghai and a small and medium-sized enterprise "specialized and special" in Shanghai.

Jianxin Biological team said:

Thanks to the strong support of new and old shareholders, the company will continue to firm direction, focus on the frontier, efficient output, do innovative products, continue to create value, benefit cancer patients and families, and return to all parties.

Mr. Lou Guoqiang, founding partner of Hongfeng Investment, said:

The field of tumor immunotherapy, differentiated and forward-looking pipeline design and layout of Jianxin Bio-Focus are in line with the focus direction of Hongfeng Investment. We are very excited to work with a team with continuous creativity and efficient execution. Hongfeng Investment continues to be optimistic about the development prospect of Jianxin Bio-technology, and hopes that the clinical research of its core products can be promoted smoothly and efficiently, so as to benefit patients at an early date.

Mr. Fu Hu, managing Partner of Calyon, said:

The team of Jianxin has developed a number of differentiated double-specific and multi-specific antibody products for the first time, which is very rare in the background of serious homogeneity of antibody drugs in China. The company's core technical team members have a solid foundation, complementary advantages, efficient and pragmatic. We are optimistic about the development potential of Jianxin and believe that under the leadership of Dr. Liu, the company will become a benchmark enterprise for the new generation of antibody drugs.

Ms. Xu Dan, partner of Zhongchuang Yongjian, said:

Jianxin Biology is a professional, dedicated, efficient and enterprising innovative drug research and development enterprise with unique platform technology. The founding team has strong research and development strength, and has profound insight and understanding of the industry and clinical needs. We expect Bis5 and Bis2 to reach the expected clinical endpoint through the hard work of the Health Care team, as well as the smooth progress of other innovative product pipelines.

Dr. Huang Bing, Executive Director of Qiao Jing Capital, said:

Following the last round of investment in health letter biology, Qiao Jing capital in this round of decisive add. We are deeply impressed by the company's forward-looking core products and the high efficiency of pipeline research and development. It is expected that the company will achieve the expected results in the pioneering clinical research of the three antibodies and the core pipeline, and the company team will continue to grow. Qiao Jing Capital will continue to spare no effort to accompany and enable the growth of enterprises.